Partin AW - Search Results

1

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.

Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA. Antonarakis ES, et al. Among authors: partin aw. J Clin Oncol. 2009 Oct 20;27(30):4986-93. doi: 10.1200/JCO.2009.21.9410. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720908 Free PMC article. Clinical Trial.

2

Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer.

Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, Epstein JI. Partin AW, et al. Cancer. 1992 Jul 1;70(1):161-8. doi: 10.1002/1097-0142(19920701)70:1<161::aid-cncr2820700126>3.0.co;2-5. Cancer. 1992. PMID: 1606538

3

The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.

Carter HB, Partin AW, Epstein JI, Chan DW, Walsh PC. Carter HB, et al. Among authors: partin aw. J Urol. 1990 Nov;144(5):1167-70; discussion 1170-1. doi: 10.1016/s0022-5347(17)39683-0. J Urol. 1990. PMID: 1700143

4

The clinical usefulness of prostate specific antigen: update 1994.

Partin AW, Oesterling JE. Partin AW, et al. J Urol. 1994 Nov;152(5 Pt 1):1358-68. doi: 10.1016/s0022-5347(17)32422-9. J Urol. 1994. PMID: 7523702 Free article. Review.

5

Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.

Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, Brendler CB, Walsh PC, Simons JW. Partin AW, et al. Urology. 1995 May;45(5):831-8. doi: 10.1016/S0090-4295(99)80091-0. Urology. 1995. PMID: 7538245

6

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. Partin AW, et al. J Urol. 1993 Jul;150(1):110-4. doi: 10.1016/s0022-5347(17)35410-1. J Urol. 1993. PMID: 7685418 Free article.

7

Influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer with established capsular penetration.

Partin AW, Borland RN, Epstein JI, Brendler CB. Partin AW, et al. J Urol. 1993 Jul;150(1):142-6; discussion 146-8. doi: 10.1016/s0022-5347(17)35416-2. J Urol. 1993. PMID: 8510234 Free article.

8

Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.

Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC, Oesterling JE. Partin AW, et al. J Urol. 1996 Apr;155(4):1336-9. J Urol. 1996. PMID: 8632568

9

The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer.

Partin AW, Carter HB. Partin AW, et al. Urol Clin North Am. 1996 Nov;23(4):531-40. doi: 10.1016/s0094-0143(05)70333-5. Urol Clin North Am. 1996. PMID: 8948408 Free article. Review.

10

Clearance rate of serum-free and total PSA following radical retropubic prostatectomy.

Partin AW, Piantadosi S, Subong EN, Kelly CA, Hortopan S, Chan DW, Wolfert RL, Rittenhouse HG, Carter HB. Partin AW, et al. Prostate Suppl. 1996;7:35-9. Prostate Suppl. 1996. PMID: 8950362

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

614 results

Search Page

Filters